PLSE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PLSE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Pulse Biosciences's total current assets for the quarter that ended in Sep. 2024 was $80.41 Mil.
The historical data trend for Pulse Biosciences's Total Current Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pulse Biosciences Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Total Current Assets | Get a 7-Day Free Trial |
![]() |
![]() |
26.40 | 22.34 | 36.63 | 62.15 | 45.33 |
Pulse Biosciences Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Total Current Assets | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
51.62 | 45.33 | 35.85 | 27.24 | 80.41 |
Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.
Pulse Biosciences's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as
Total Current Assets | = | Cash, Cash Equivalents, Marketable Securities | + | Total Receivables | + | Total Inventories | + | Other Current Assets |
= | 44.365 | + | 0 | + | 0 | + | 0.963 | |
= | 45.33 |
Pulse Biosciences's Total Current Assets for the quarter that ended in Sep. 2024 is calculated as
Total Current Assets | = | Cash, Cash Equivalents, Marketable Securities | + | Total Receivables | + | Total Inventories | + | Other Current Assets |
= | 79.033 | + | 0 | + | 0 | + | 1.381 | |
= | 80.41 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.
Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.
Pulse Biosciences (NAS:PLSE) Total Current Assets Explanation
In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.
Pulse Biosciences's Liquidation Value for the quarter that ended in Sep. 2024 is
Liquidation value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 79.033 | - | 13.915 | + | 0.75 * 0 | + | 0.5 * 0 |
= | 65.12 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Pulse Biosciences's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Robert W Duggan | director, 10 percent owner | 611 SOUTH FORT HARRISON AVE, SUITE 306, CLEARWATER FL 33756 |
Kevin Patrick Danahy | officer: Chief Commercial Officer | 50 TEABERRY LANE, BRAINTREE MA 02184 |
Mitchell E. Levinson | director | 3957 POINT EDEN WAY, HAYWARD CA 94545 |
Manmeet Singh Soni | director | C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085 |
Van Den Broek Richard | director | 73 ARCH STREET, 1ST FLOOR, GREENWICH CT 06830 |
Maky Zanganeh | director | 51 ADAM WAY, ATHERTON CA 94027 |
Sandra A. Gardiner | officer: CFO & EVP Admin. and Finance | CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
Shelley D Spray | director | C/O PULSE BIOSCIENCES, INC., 3957 POINT EDEN WAY, HAYWARD CA 94545 |
Laureen Debuono | director | |
Ed Ebbers | officer: EVP & GM, Dermatology | 3957 POINT EDEN WAY, HAYWARD CA 94545 |
Kenneth A Clark | director | C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE., SUNNYVALE CA 94085 |
Fogarty Thomas J M D | director | C/O VENTURE LAW GROUP, 2800 SAND HILL RD STE 270, MENLO PARK CA 94025 |
Thierry B. Thaure | director | 3957 POINT EDEN WAY, HAYWARD CA 94545 |
Robert J. Greenberg | director | 12744 SAN FERNANDO ROAD, BLDG. 3, SYLMAR CA 91342 |
Brian B Dow | officer: CFO & SVP Admin. and Finance | 5675 GIBRALTAR AVENUE, PLEASANTON CA 94588 |
From GuruFocus
By Business Wire • 01-03-2025
By Business Wire • 08-12-2024
By GuruFocus News • 01-21-2025
By Business Wire • 10-21-2024
By Business Wire • 12-23-2024
By GuruFocus News • 01-10-2025
By GuruFocus News • 01-13-2025
By Business Wire • 01-21-2025
By GuruFocus News • 02-04-2025
By GuruFocus Research • 08-13-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.